Low-dose UVA1 phototherapy for scleroderma: what benefit can we expect?
Posted 10 January 2013 - 12:55 PM
In patients with morphea, a marked improvement was found in 77.8% patients and a moderate improvement was found in 11.1% patients. In the systemic scleroderma group, a patient with complete remission of the skin sclerosis is emphasized. PubMed. J Eur Acad Dermatol Venereol. 2012 May;26(5):619-26. (Also see: Morphea Treatments and Skin Fibrosis Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)